Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis
暂无分享,去创建一个
Guo Wang | Jun-Li Deng | Yun-hua Xu | Guo Wang | Jun-Li Deng | Yun-Hua Xu
[1] Bioinformatics analysis reveals disturbance mechanism of MAPK signaling pathway and cell cycle in Glioblastoma multiforme. , 2014, Gene.
[2] Qiang Liu,et al. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients. , 2015, Oncology reports.
[3] Cheng Wang,et al. Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses , 2018, Journal of cellular biochemistry.
[4] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[5] Gordon B Mills,et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.
[6] T. Mak,et al. Targeting Mitosis in Cancer: Emerging Strategies. , 2015, Molecular cell.
[7] Yuan-Shan Zhu,et al. H 19 lncRNA mediates 17 β-estradiol-induced cell proliferation in MCF-7 breast cancer cells , 2015 .
[8] Yan Peng,et al. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. , 2015, Oncology reports.
[9] Yuan-Yuan Pei,et al. Kinesin family member 11 contributes to the progression and prognosis of human breast cancer , 2017, Oncology letters.
[10] R. Schlegel,et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells , 2014, eLife.
[11] Davide Heller,et al. STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..
[12] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[13] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[14] A. Lánczky,et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.
[15] Amy M. Sitapati,et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] J. Ji,et al. CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance , 2014, PloS one.
[17] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[18] Wanqing Chen,et al. Cancer statistics: updated cancer burden in China. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[19] Donghai Huang,et al. Genome-wide analyses of long noncoding RNA expression profiles correlated with radioresistance in nasopharyngeal carcinoma via next-generation deep sequencing , 2016, BMC Cancer.
[20] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[21] Nathanael S Gray,et al. MELK is not necessary for the proliferation of basal-like breast cancer cells , 2017, eLife.
[22] C. Orengo,et al. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma , 2006, BMC Genomics.
[23] Y. Miyoshi,et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] G. Evan,et al. Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.
[25] Gary D. Bader,et al. An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.
[26] Wei Zhang,et al. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer , 2017, Oncotarget.
[27] Yueyin Pan,et al. Novel key genes in triple‐negative breast cancer identified by weighted gene co‐expression network analysis , 2019, Journal of cellular biochemistry.
[28] Chengqiong Mao,et al. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[29] C. Miller,et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases , 2011, Breast Cancer Research.
[30] Enhao Fang,et al. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis. , 2017, Cancer biomarkers : section A of Disease markers.
[31] Ping Chen,et al. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth , 2016, Oncotarget.
[32] Wei Zhang,et al. COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value , 2016, Oncotarget.
[33] Thomas C. Wiegers,et al. Text Mining Effectively Scores and Ranks the Literature for Improving Chemical-Gene-Disease Curation at the Comparative Toxicogenomics Database , 2013, PloS one.
[34] M. B. Davis,et al. breast cancer cells , 2009 .
[35] A. Lin,et al. MELK expression correlates with tumor mitotic activity but is not required for cancer growth , 2018, eLife.
[36] Pradip De,et al. PI3K‐AKT‐mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials , 2017, Pharmacology & therapeutics.
[37] Pedro Fonseca,et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data , 2017, Journal of extracellular vesicles.
[38] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[39] Gang Yin,et al. CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer , 2018, Cancer management and research.
[40] Chad J. Creighton,et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.
[41] W. Ghali,et al. Kaplan-Meier survival analysis overestimates cumulative incidence of health-related events in competing risk settings: a meta-analysis. , 2018, Journal of clinical epidemiology.
[42] Qiang Liu,et al. RRM 1 , TUBB 3 , TOP 2 A , CYP 19 A 1 , CYP 2 D 6 : Difference between mRNA and protein expression in predicting prognosis of breast cancer patients , 2015 .
[43] I. Andrulis,et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. , 2009, Journal of the National Cancer Institute.
[44] K. Friedrich,et al. Impact of breast cancer subtypes and patterns of metastasis on outcome , 2015, Breast Cancer Research and Treatment.
[45] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[46] Wenqing Li,et al. CCNB1 is a prognostic biomarker for ER+ breast cancer. , 2014, Medical hypotheses.
[47] Terukazu Nakamura,et al. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. , 2014, Urologic oncology.